Fatal Course of Patients with metastatic Dermatofibrosarcoma protuberans under Therapy with Imatinib mesylate (Glivec®)

被引：0
|
作者：
Babic, V [1 ]
Dabrowski, E. [1 ]
Dippel, E. [1 ]
机构：
[1] Klinikum Ludwigshafen, Hautklin, Ludwigshafen, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2015年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P144
引用
收藏
页码：163 / 163
页数：1
相关论文
共 50 条
  • [41] Imatinib as effective therapy for dermatofibrosarcoma protuberans: proof of concept of the autocrine hypothesis for cancer
    Handolias, Despina
    McArtbur, Grant A.
    FUTURE ONCOLOGY, 2008, 4 (02) : 211 - 217
  • [42] Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation
    Rutkowski, P.
    Klimczak, A.
    Lugowska, I.
    Jagielska, B.
    Wagrodzki, M.
    Debiec-Rychter, M.
    Pienkowska-Grela, B.
    Switaj, T.
    EJSO, 2017, 43 (06): : 1134 - 1141
  • [43] Tuberculous and Non-Tuberculous Granulomatous Lymphadenitis in Patients Receiving Imatinib Mesylate (Glivec) for Metastatic Gastrointestinal Stromal Tumor
    Agaimy, Abbas
    Brueckl, Valeska
    Schmidt, Daniela
    Krieg, Stephanie
    Ullrich, Evelyn
    Meidenbauer, Norbert
    CASE REPORTS IN ONCOLOGY, 2013, 6 (01): : 134 - 142
  • [44] Imatinib mesylate (Gleevec®/Glivec®):: A new therapy for chronic myeloid leukemia and other malignancies
    Hernández-Boluda, JC
    Cervantes, F
    DRUGS OF TODAY, 2002, 38 (09) : 601 - 613
  • [45] Thrombocytopenia induced by imatinib mesylate (Glivec) in patients with chronic myelogenous leukemia: Is 400 mg daily of imatinib mesylate an optimal starting dose for Japanese patients?
    Miyazawa, K
    Nishimaki, J
    Katagiri, T
    Sashida, G
    Shoji, N
    Kawakubo, K
    Suzuki, A
    Shimamoto, T
    Gotoh, A
    Kuriyama, Y
    Ito, Y
    Tauchi, T
    Kawanishi, Y
    Kimura, Y
    Ohyashiki, K
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2003, 77 (01) : 93 - 95
  • [46] Thrombocytopenia Induced by Imatinib Mesylate (Glivec) in Patients with Chronic Myelogenous Leukemia: is 400 mg Daily of Imatinib Mesylate an Optimal Starting Dose for Japanese Patients?
    Keisuke Miyazawa
    Jiroh Nishimaki
    Tomoko Katagiri
    Goro Sashida
    Nahoko Shoji
    Ken Kawakubo
    Akitaka Suzuki
    Takashi Shimamoto
    Akihiko Gotoh
    Yuzuru Kuriyama
    Yoshikazu Ito
    Tetsuzo Tauchi
    Yoshikazu Kawanishi
    Yukihiko Kimura
    Kazuma Ohyashiki
    International Journal of Hematology, 2003, 77 : 93 - 95
  • [47] A favorable outcome of advanced dermatofibrosarcoma protuberans under treatment with sunitinib after imatinib failure
    Xiao, Wei
    Que, Yi
    Peng, Ruiqing
    Ding, Ya
    Zhao, Jingjing
    Wen, Xizhi
    Weng, Desheng
    Zhang, Xiaoshi
    Guan, Yuanxiang
    Zhang, Xing
    ONCOTARGETS AND THERAPY, 2018, 11 : 2439 - 2443
  • [48] Case Presentation - Combination Therapy with Imatinib and surgical Excision in extensive Dermatofibrosarcoma protuberans of the Face
    Weihsengruber, F.
    Jungbauer, L.
    Gaggl, A.
    Rappersberger, K.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 (09): : 939 - 939
  • [49] Neo-adjuvant Therapy of Dermatofibrosarcoma protuberans with Imatinib: A multicenter Phase II Study of the ADO
    Ugurel, S.
    Mentzel, T.
    Utikal, J.
    Helmbold, P.
    Mohr, P.
    Pfoehler, C.
    Schiller, M.
    Hauschild, A.
    Hein, R.
    Kaempgen, E.
    Kellner, I
    Leverkus, M.
    Becker, J.
    Stroebel, P.
    Schadendorf, D.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 (09): : 909 - 909
  • [50] Heterogeneity of response to imatinib-mesylate (Glivec) in patients with hypereosinophilic syndrome: Implications for dosing and pathogenesis
    Musto, P
    Falcone, A
    Sanpaolo, G
    Bodenizza, C
    Perla, G
    Minervini, MM
    Cascavilla, N
    Dell'Olio, M
    La Sala, A
    Mantuano, S
    Melillo, L
    Nobile, M
    Scalzulli, PR
    Bisceglia, M
    Carella, AM
    LEUKEMIA & LYMPHOMA, 2004, 45 (06) : 1219 - 1222
12345